Vaccine From Asian Bird Flu Strains Shows Effective In Trials
This article was originally published in PharmAsia News
Executive Summary
A U.S. drug maker using Vietnam, Hong Kong and Indonesian bird-flu viruses has developed a vaccine that has survived Phase II trials. Baxter International's Celvapan showed in second-stage trials to be capable of protecting 76 percent of the participants from the Vietnam and Hong Kong strains and 45 percent of them from the Indonesian strain. The success of the vaccine so far is seen as promising for a faster way of developing a vaccine to avoid a global pandemic of the H5N1 avian influenza. Baxter said its vaccine-making method could allow production of a new vaccine within as little as 12 weeks. (Click here for more
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.